Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Crinetics Pharmaceuticals Inc

CRNX
Current price
42.97 USD +0.61 USD (+1.44%)
Last closed 43.01 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 474 876 672 USD
Yield for 12 month +149.54 %
1Y
3Y
5Y
10Y
15Y
CRNX
21.11.2021 - 28.11.2021

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 6055 Lusk Boulevard, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

57.92 USD

P/E ratio

Dividend Yield

Current Year

+4 013 000 USD

Last Year

+4 737 000 USD

Current Quarter

Last Quarter

+346 000 USD

Current Year

+2 915 000 USD

Last Year

+4 737 000 USD

Current Quarter

-262 000 USD

Last Quarter

+73 000 USD

Key Figures CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -221 510 000 USD
Operating Margin TTM -5547.17 %
PE Ratio
Return On Assets TTM -28.18 %
PEG Ratio
Return On Equity TTM -50.16 %
Wall Street Target Price 57.92 USD
Revenue TTM 4 013 000 USD
Book Value 7.91 USD
Revenue Per Share TTM 0.069 USD
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -125 488 000 USD
Earnings Share -3.69 USD
Diluted Eps TTM -3.69 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRNX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 739.609
Price Sales TTM 865.905
Enterprise Value EBITDA -13.3992
Price Book MRQ 6.4456

Financials CRNX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRNX

For 52 weeks

15.76 USD 49.58 USD
50 Day MA 41.69 USD
Shares Short Prior Month 5 009 254
200 Day MA 30.69 USD
Short Ratio 5
Shares Short 4 912 712
Short Percent 6.92 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics